骨质疏松症是抗再吸收药物(ARD)最常见的适应症。药物相关的颌骨坏死(MRONJ)是ARD的严重并发症。多种危险因素会增加MRONJ的风险,其中之一是ARD摄入的持续时间,对于骨质疏松症病例,这通常是延长的。MRONJ的预防依赖于治疗医生和牙科医生之间的协作护理。因此,关于MRONJ及其预防策略的知识对两个团队都至关重要。
■本研究旨在评估医生对骨质疏松患者MRONJ的知识和态度。另一个目的是制定预防MRONJ的建议。
■通过在线调查,基本信息,如练习地点,培训,知识,感知,收集了医生对骨质疏松症患者ARDs和MRONJ的态度。对所有变量进行统计分析,并探讨了它们的相关性。
■共有221名医生参与了调查:34.8%是风湿病专家,25.3%是内分泌学家,8.6%是家庭医生,5.9%是骨科医生,内科医师占5.9%。其中,58.0%的人报告有6年以上的经验。只有78.7%的人知道MRONJ,并认识到双膦酸盐(BP)可以促进MRONJ。相比之下,56.0%认为denosumab是MRONJ的致病因素。ARD治疗的持续时间以及ARD前后的牙科护理已知会影响62%和65.6%的参与者的MRONJ风险。分别。只有41.6%和31.2%的参与者在BP和denosumab治疗之前告知患者MRONJ,分别。只有25.3%和20.8%的患者在接受BP和denosumab治疗之前将患者转诊给牙医,分别。总的来说,65.6%的参与者对MRONJ持否定态度,34.4%持积极态度。与其他专家相比,风湿病学家(55.8%)大多持积极态度(p<0.001)。更多年的经验与更高的知识水平和积极的态度有关。
■这项研究的结果发现了意识方面的明显差距,医生对骨质疏松症患者MRONJ的知识和态度。强烈推荐有关ARD和MRONJ风险的继续教育计划。
Osteoporosis is the most common indication for antiresorptive drugs (ARDs). Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of ARDs. Multiple risk factors can increase the risk of MRONJ, one of which is the duration of ARD intake, which is usually prolonged for osteoporosis cases. Prevention of MRONJ relies on collaborative care between treating physicians and dental practitioners. Therefore, knowledge about MRONJ and its prevention strategies is crucial for both teams.
UNASSIGNED: This study aimed to assess the knowledge and attitudes of physicians toward MRONJ in osteoporosis patients. Another aim was to develop recommendations for the prevention of MRONJ.
UNASSIGNED: Through an online survey, basic information such as the practice location, training, knowledge, perceptions, and attitudes of physicians regarding ARDs and MRONJ in osteoporosis patients was collected. Statistical analysis was performed for all variables, and their correlations were explored.
UNASSIGNED: A total of 221 physicians participated in the survey: 34.8% were rheumatologists, 25.3% were endocrinologists, 8.6% were family medicine physicians, 5.9% were orthopedists, and 5.9% were internal medicine physicians. Of them, 58.0% reported more than 6 years of experience. Only 78.7% were aware of MRONJ and recognized that bisphosphonates (BPs) can contribute to MRONJ. In contrast, 56.0% recognized denosumab as a causative factor for MRONJ. Duration of ARD therapy and pre- and post-ARD dental care were known to influence the risk of MRONJ by 62% and 65.6% of the participants, respectively. Only 41.6% and 31.2% of participants informed patients about MRONJ prior to BP and denosumab therapy, respectively. Only 25.3% and 20.8% referred patients to dentists before BP and denosumab therapy, respectively. Overall, 65.6% of the participants had a negative attitude toward MRONJ, and 34.4% had a positive attitude. A positive attitude was mostly observed among rheumatologists (55.8%) compared to other specialists (p <0.001). More years of experience were associated with a higher level of knowledge and positive attitude.
UNASSIGNED: The findings of this study identified a notable gap in the awareness, knowledge and attitudes of physicians regarding MRONJ in osteoporosis patients. Continuing education programs about ARDs and MRONJ risk are highly recommended.